Lifecore Biomedical to Participate at DCAT Week 2026
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) will participate in DCAT Week 2026, March 23-26, 2026, in New York City. Lifecore's team will host customers and prospective partners to discuss development and manufacturing solutions for injectable programs. Meetings are available by contacting cdmo@lifecore.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed moves, with names like KMDA up 3.53% and SXTC down 4.21%, and no same-day peer news, indicating the DCAT Week update is company-specific rather than part of a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Inducement equity grants | Neutral | +0.4% | Announced RSU and option grants to two newly hired employees. |
| Dec 18 | Index inclusion | Positive | -0.6% | Planned addition to the Nasdaq Biotechnology Index (NBI). |
| Dec 17 | New CDMO agreement | Positive | +9.9% | Signed CDMO master services deal with large multinational pharma partner. |
| Dec 16 | Conference participation | Neutral | -2.2% | Planned participation in the 44th Annual J.P. Morgan Healthcare Conference. |
| Nov 11 | Investor conferences | Neutral | +6.2% | Announced participation in Jefferies and Stephens investor conferences. |
Stock has generally reacted modestly to routine corporate and conference news, with stronger moves around major CDMO contract wins.
Over the past six months, Lifecore reported several corporate and investor-relations milestones. A new CDMO master services agreement with a large multinational customer on Dec 17, 2025 saw the strongest reaction, with a 9.86% move. Index inclusion in the Nasdaq Biotech Index on Dec 18, 2025 produced a slight decline of 0.59%. Participation announcements for major conferences in November and January generated mixed but moderate moves between about -2% and +6%, consistent with today’s routine DCAT Week participation news.
Regulatory & Risk Context
An effective Form S-3 shelf registration dated Sep 22, 2025 covers up to 20,456,637 common shares for resale by selling stockholders, including issued shares and shares issuable upon conversion of Series A Convertible Preferred Stock with a 7.5% PIK dividend and conversion terms described in the filing. The filing also notes an adverse opinion on internal control over financial reporting as of May 25, 2025 by the prior auditor.
Market Pulse Summary
This announcement highlights Lifecore’s participation at DCAT Week 2026 to meet customers and prospective partners for injectable CDMO services from March 23–26, 2026. Historically, similar conference and investor-event updates have produced modest stock moves versus larger reactions to major CDMO contracts or financial results. Given an active S-3 for 20,456,637 resalable shares and prior internal-control findings, investors may focus on execution, balance-sheet details, and future contract wins alongside such visibility events.
Key Terms
cdmo technical
AI-generated analysis. Not financial advice.
CHASKA, Minn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at DCAT Week 2026. The conference will take place March 23-26, 2026, in New York City.
Details regarding Lifecore’s participation are as follows:
- DCAT Week 2026
Details: Lifecore team will host customers and prospective partners to discuss development and manufacturing solutions for existing and new injectable programs.
Conference Dates: March 23-26, 2026
Location: New York, NY
If you are interested in meeting with Lifecore during DCAT week, please reach out to us at: cdmo@lifecore.com.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 sdiaz@vidasp.com Tim Brons (Media) 415-675-7402 tbrons@vidasp.com Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 ryan.lake@lifecore.com
FAQ
When will Lifecore (LFCR) attend DCAT Week 2026 in New York?
How can investors or partners schedule meetings with Lifecore (LFCR) at DCAT Week 2026?
What will Lifecore (LFCR) discuss at DCAT Week 2026?
Where is DCAT Week 2026 taking place for Lifecore (LFCR)?
Is Lifecore (LFCR) offering meetings for prospective partners at DCAT Week 2026?
